Advancing Neuromuscular Research and Care: Highlights from the 2025 NMD4C Annual Meeting
Last month, NMD4C hosted its 2025 Annual Meeting in Ottawa
It was a full day of collaborative sessions, strategic discussions and networking that brought together clinicians, researchers, trainees, and partners from across Canada to advance neuromuscular research and care.
Meeting highlights included:
- A recognition ceremony celebrating Early Career awardees and NM fellowship funding recipients
- Flash talk presentations showcasing the work of early-career researchers
- Networking breaks to foster collaboration and community building
- Parallel group discussions to address key priorities in neuromuscular research and care:
-
- Clinical Sessions explored:
- Implementation strategies and awareness-building for new SBMA guidelines
- Health administrative data linkage for SBMA, OPMD, SMA, and DMD with the CNDR
- Barriers to implementing MRI and ultrasound into clinical practice
- Planning for gene therapy in Canada
- Development of combination treatment guidelines for SMA
- Establishing and integrating DM1 outcome measures with CNDR datasets
- Cross-disciplinary and Basic Science Sessions focused on:
- Collaborative grant design and funding pathway exploration
- Academic retention and postdoc-to-PI transition support
- Enhancing access to shared resources and fostering preclinical-clinical collaborations
- Synthesizing insights to prioritize next steps for cross-disciplinary initiatives
- Clinical Sessions explored:
We extend our sincere thanks to our funders — Muscular Dystrophy Canada (MDC) and the Canadian Institutes of Health Research (CIHR) — and to all members, discussion leads, and partners who contributed to the success of this event.
Together, we are strengthening Canada’s neuromuscular research and care community.
We look forward to hosting our 2026 Annual Meeting just ahead of the WCNMC 2026 in Calgary on September 25, 2026!
See snapshots of the annual meeting in Our Gallery
Read next...
New Publication from the NMD4C Clinical Trial Network Strengthens Trial Capacity in Canada
We are pleased to share a new publication from the NMD4C Clinical Trial Network led by Kerri Lynn Schellenberg, Homira Osman, Maria Masnata, Rhiannon Hicks, Corinne Kagan, Ana Stosic, Stacey Lintern, Erin Beattie, Drs. Hanns Lochmüller, Craig Campbell, and Jean K Mah. This work focuses on the implementation of a coordinated Canadian neuromuscular clinical trial network to enhance trial readiness, capacity, and access in rare disease research.
Canadian-Led Phase II Studies Advance Vamorolone Evidence in Duchenne Muscular Dystrophy
NMD4C investigators contributed to two phase II studies evaluating vamorolone in boys with Duchenne muscular dystrophy across early childhood and adolescence, demonstrating safety, favorable pharmacokinetics, and potential efficacy. Led by Dr. Jean Mah and conducted across Canadian clinical trial sites with national and industry collaborators, the findings supported Health Canada approval of vamorolone as the first treatment for DMD in Canada. Leaders from both the clinical and patient advocacy communities, including Defeat Duchenne Canada, highlighted the impact of collaboration among patients, families, clinicians, and researchers in advancing care and improving access to new therapies.
Advancing AFC in Neuromuscular Medicine: Program Launch & September Workshop
The Royal College has approved National Training Standards for the AFC in Neuromuscular Medicine, creating a formal pathway to recognize enhanced competence with the DRCPSC credential. This designation establishes a national training standard, supports portable certification, and strengthens clinical capacity across Canada. PGME offices can now apply to offer accredited AFC programs, with a goal of five programs submitting applications by the end of 2026.